

# Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal

NCT05995535

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	University of Pennsylvania
<b>Enrollment</b>	150 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Male and/or female subjects e 18 years of age
- Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months
- Interested in opioid antagonist treatment
- Used opioids in 20 or more of the last 30 days
- A stable address in the local area; not planning to move in the next 60 days.
- ... and 4 more (see full listing online)

### Exclusion (19)

- Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission)
- Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification
- Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine
- Pending incarceration or plans to leave the immediate area in the next 30 days
- Homicidal or otherwise behaviorally disturbed requiring immediate attention
- ... and 14 more (see full listing online)

## Locations (2 total)

---

Mountain Manor Treatment Center, Baltimore, Maryland, United States  
University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania, United States